Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries

Vaccine

Volumn 27, Issue 40, 2009, Pages 5519-5529

  Colantonio, Lisandro ^a,b   Gómez, Jorge A ^c   Demarteau, Nadia ^d,e   Standaert, Baudouin ^e   Pichón Rivière, Andrés ^a,b   Augustovski, Federico ^a,b,f  

^a INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c GlaxoSmithKline   (Argentina)

^d IMS HEOR   (Belgium)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

Cost effectiveness analysis; Papillomavirus vaccines; Uterine cervical neoplasms

Indexed keywords

WART VIRUS VACCINE;

ARGENTINA; ARTICLE; BRAZIL; CANCER IMMUNIZATION; CHILE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; MEXICO; PERU; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CANCER;

CANCER VACCINES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; LATIN AMERICA; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 68349152633     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.097     Document Type: Article

References (103)

1. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87 11 (1995) 796-802
2. Muñoz N., Castellsague X., de González A.B., and Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24 S3 (2006) S1-S10
3. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 89 1 (2003) 101-105
4. Clifford G.M., Smith J.S., Plummer M., Muñoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 1 (2003) 63-73
5. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 3 (2007) 621-632
6. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0. IARC Press (International Agency for Research on Cancer); 2004. Available from: http://www-dep.iarc.fr/globocan/downloads.htm [Cited: February 7, 2007].
7. Parkin D.M., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24 suppl. 3 (2006) S11-S25
8. Yang B.H., Bray F.I., Parkin D.M., Sellors J.W., and Zhang Z.F. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 109 3 (2004) 418-424
9. International Agency for Research on Cancer. Handbooks of Cancer Prevention. Cervix cancer screening vol. 9 (2004), IARC Press, Lyon
10. Denny L., Quinn M., and Sankaranarayanan R. Chapter 8: screening for cervical cancer in developing countries. Vaccine 24 suppl. 3 (2006) S71-S77
11. Gakidou E., Nordhagen S., and Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 5 6 (2008) e132
12. Eluf-Neto J., and Nascimento C.M. Cervical cancer in Latin America. Semin Oncol 28 2 (2001) 188-197
13. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
14. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 19 (2007) 1928-1943
15. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 19 (2007) 1915-1927
16. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
17. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 8 (2004) 604-615
18. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 11 (2004) 1915-1923
19. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'Shea M.K., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25 33 (2007) 6257-6270
20. Kane M.A., Sherris J., Coursaget P., Aguado T., and Cutts F. Chapter 15: HPV vaccine use in the developing world. Vaccine 24 suppl. 3 (2006) S132-S139
21. Franco E.L., Cuzick J., Hildesheim A., and de Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 suppl. 3 (2006) S171-S177
22. Insinga R.P., Dasbach E.J., and Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36 11 (2003) 1397-1403
23. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 6 (2003) 781-789
24. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 1 (2003) 37-48
25. Kim J.J., Kobus K., Salomon J., Kuntz K.M., Holtan M., and Goldie S. Cost-effectiveness analysis of prophylactic human papillomavirus vaccination and screening in Brazil. 28th Annual Meeting of the Society for Medical Decision Making. 2006 October 15-18; Boston, MA: Society for Medical Decision Making (2006)
26. Kim J.J., Andres-Beck B., and Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 97 (2007) 1322-1328
27. Suárez E., and Prieto M. Cervical cancer: the Chilean perspective. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95 suppl. 1 (2006) S235-S238
28. Sepúlveda C., and Prado R. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience. Cancer Detect Prev 29 5 (2005) 405-411
29. Demarteau N., Detournay B., El Hasnaoui A., Standaert B., and Annemans L. Outcome validation of a succinct HPV infection model for France (PCN 56). ISPOR 9th Annual European Congress. 2006 October 28-31; Copenhagen; International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2006)
30. Demarteau N., Detournay B., El Hasnaoui A., Standaert B., and Annemans L. Long term clinical effect of an HPV-vaccine for the prevention of cervical cancer in France in relation to age of vaccination: results from a Markov model (PCN 55). ISPOR 9th Annual European Congress. 2006 October 28-31; Copenhagen: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2006)
31. Demarteau N., Ferko N., Martín A., Standaert B., and Annemans L. Evaluating the cost-effectiveness of HPV vaccination: a comparison of succinct versus detailed modelling approaches in the UK (P-172). 23rd International Papillomavirus Conference & Clinical Workshop. 2006 September 1-7; Prague: International Papillomavirus Society (2006)
32. Debicki D., Ferko N., Demarteau N., Gallivan S., Bauch C., Anonychuk A., et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 26S (2008) F16-F18
33. Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Voorhorst F.J., Bezemer P.D., et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358 9295 (2001) 1782-1783
34. Melnikow J., Nuovo J., Willan A.R., Chan B.K., and Howell L.P. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92 4 Pt 2 (1998) 727-735
35. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 2 (2001) 153-156
36. Beck J.R., Pauker S.G., Gottlieb J.E., Klein K., and Kassirer J.P. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 73 6 (1982) 889-897
37. Harper D.M., Gall S., Naud P., Quint W., Dubin G., Jenkins D., et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow-up through 6.4 years in women vaccinated with CERVARIX (GSKS HPV 16/18 AS04 Candidate vaccine). SGO's Annual Meeting on Women's Cancer. 2008 March 10, 2008; Tampa, Florida: Society of Gynecologic Oncologists (2008)
38. Health Outcomes Data Repository (HODaR). Cardiff Research Consortium. Available from: https://www.crc-limited.co.uk/portal/hodar.html [Cited: December, 2007].
39. Insinga R., Glass A., and Rush B. Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses (Abstract W-02). 22nd International Papillomavirus Conference & Clinical Workshop. 2005 April 30-May 6; Vancouver, BC, Canada: International Papillomavirus Society (2005)
40. Myers E.R., Green S., and Lipkus I. Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation. 21st International Papillomavirus Conference. 2004 February 20-27; México DF, México: International Papillomavirus Society (2004)
41. Gold M.R., Franks P., McCoy K.I., and Fryback D.G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 36 6 (1998) 778-792
42. Gordillo-Tobar A. Costo y desempeño de las pruebas de tamizaje y costos del tratamiento del cáncer cervicouterino en la región de San Martín (Perú) (2005), Área Técnica de Prevención y Control de Enfermedades, Unidad de Enfermedades No Transmisibles. Organización Panamericana de la Salud, Washington
43. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., Gordillo-Tobar A., Levin C., Mahe C., et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 353 20 (2005) 2158-2168
44. Goldhaber-Fiebert J.D., and Goldie S.J. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc 4 (2006) 13
45. Marmolejo-Saucedo L, Reynales-Shigematsu LM, Jimenez-Ruiz JA, Suchil-Bernal L, Mohar-Betancourt A, Lazcano-Ponce E. Costos del diagnóstico y tratamiento de las enfermedades relacionadas con el virus del papiloma humano en el Instituto Nacional de Cancerología, México. Cuernavaca, México: Instituto Nacional de Salud Pública; unpublished work.
46. Urriola R. Chile: social protection in health. Rev Panam Salud Publica 20 4 (2006) 273-286
47. Rodrigues dos Santos N. The evolution of the Brazilian National Health System, strategic courses of action and strategies to understand these actions. Cien Saude Colet 12 2 (2007) 429-435
48. Insua JT, Tatti S, Festa H. Utilización de servicios y costos de la prevención y el tratamiento de infección por Virus del Papiloma Humano (HPV) en dos hospitales Públicos de la Argentina: Reporte preliminar. Buenos Aires, Argentina; unpublished work.
49. Pichón-Rivière A, Regueiro A, Souto A, Augustovski F. Base de datos de costos sanitarios Argentinos. Documento Técnico No 3. Buenos Aires: Instituto de Efectividad Clínica y Sanitaria (IECS); 2004. Last Update: 2007 July. Available from: http://www.iecs.org.ar/iecs-visor-publicacion.php?cod_publicacion=146&origen_publicacion=publicaciones [Cited: November, 2007].
50. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., and Russell L.B. Recommendations of the Panel on cost-effectiveness in health and medicine. JAMA 276 15 (1996) 1253-1258
51. Sachs J.D. Macroeconomics and health: investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health (2001), World Health Organization, Geneva
52. Total Gross Domestic Product (GDP) 2006. World Development Indicators database World Bank; 2007. Last Update: 2007 June 1. Available from: http://siteresources.worldbank.org/DATASTATISTICS/Resources/GDP.pdf [Cited: October 4, 2007].
53. Purchasing-Power-Parity (PPP) Gross Domestic Product (GDP) 2006. World Bank; 2007. Last Update: 2007 September 14. Available from: http://siteresources.worldbank.org/DATASTATISTICS/Resources/GDP_PPP.pdf [Cited: September 28, 2007].
54. Population 2006. World Development Indicators database World Bank; 2007. Last Update: 2007 September 14. Available from: http://siteresources.worldbank.org/DATASTATISTICS/Resources/POP.pdf [Cited: September 28, 2007].
55. David M.P., Hardt K., Tibaldi F., Dubin G., and Descamps D. Long-term persistence of detectable anti-HPV-16 and anti-HPV-18 antibodies induced by CervarixTM: modelling of sustained antibody responses. 26th Annual Meeting of the European Society for Paediatric Infectious Diseases. 2008 May 13-17; Graz, Austria: European Society for Paediatric Infectious Diseases (ESPID) (2008)
56. Suarez E., Smith J., Bosch X., Nieminen P., Chen C.J., Torvinen S., et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 26 suppl. 5 (2008) F29-F45
57. Miller B.A., Chu K.C., Hankey B.F., and Ries L.A. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control 19 3 (2008) 227-256
58. Miller B.A., Kolonel L.N., Bernstein L., Young J.J., Swanson G.M., West D., et al. Racial/ethnic patterns of cancer in the United States, 1988-1992 (1996), National Cancer Institute (NIH), Bethesda, MD
59. Garnett G.P. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 191 suppl. 1 (2005) S97-S106
60. Claxton K., Sculpher M., Culyer A., McCabe C., Briggs A., Akehurst R., et al. Discounting and cost-effectiveness in NICE-stepping back to sort out a confusion. Health Econ 15 1 (2006) 1-4
61. Brouwer W.B., Niessen L.W., Postma M.J., and Rutten F.F. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 331 7514 (2005) 446-448
62. Gravelle H., Brouwer W., Niessen L., Postma M., and Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ 16 3 (2007) 307-317
63. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 1 (2007) 28-41
64. Pichón-Rivière A, Augustovski F, Alcaraz A, Bardach A, Colantonio L, García Martí S, et al. Efficacy of the human papillomavirus (HPV) vaccine. Report IRR No 86. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS); 2006. Available from: http://www.iecs.org.ar/.
65. Insinga R.P., Dasbach E.J., Elbasha E.H., Puig A., and Reynales-Shigematsu L.M. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 26 1 (2007) 128-139
66. Franco E.L. Commentary: health inequity could increase in poor countries if universal HPV vaccination is not adopted. BMJ 335 7616 (2007) 378-379
67. Goldie S.J., Diaz M., Constenla D., Alvis N., Andrus J.K., and Kim S.Y. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 26S (2008) L59-L72
68. Rogoza R.M., Ferko N., Bentley B., Meijer C., Berkhof J., Wang K.L., et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 26S (2008) F46-F58
69. Observatorio Demográfico No.2: Población económicamente activa. Santiago, Chile: Comisión Económica para América Latina y el Caribe (CEPAL). Centro Latinoamericano y Caribeño de Demografía. Naciones Unidas; 2006.
70. Tatti S, Fleider L, Tinnirello MA, Chabelski C, Vighi S, Provenzano S. Avances en la prevención del cáncer cervical: "del PAPANICOLAU a la VACUNA PROFILACTICA para el PAPILOMAVIRUS HUMANA (HPV)". Buenos Aires: Hospital de Clínicas "José de San Martín", Universidad de Buenos Aires; unpublished work.
71. Fahey M.T., Irwig L., and Macaskill P. Meta-analysis of PAP test accuracy. Am J Epidemiol 141 7 (1995) 680-689
72. Almonte M., Ferreccio C., Winkler J.L., Cuzick J., Tsu V., Robles S., et al. Cervical screening by visual inspection, HPV testing, liquid-based and conventional cytology in Amazonian Peru. Int J Cancer 121 4 (2007) 796-802
73. Bleggi Torres L.F., Werner B., Totsugui J., Collaco L.M., Araujo S.R., Huculak M., et al. Cervical cancer screening program of Parana: cost-effective model in a developing country. Diagn Cytopathol 29 1 (2003) 49-54
74. Lazcano-Ponce E., Herrero R., Munoz N., Cruz A., Shah K.V., Alonso P., et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 91 3 (2001) 412-420
75. Viva mulher. Câncer do Colo do Útero: Informações Técnico-Gerenciais e Ações Desenvolvidas (2002), Instituto Nacional de Câncer, Rio de Janeiro
76. Flores-Luna L., Salazar-Martinez E., Escudero-De los Rios P., Gonzalez-Lira G., Zamora-Munoz S., and Lazcano-Ponce E. Prognostic factors related to cervical cancer survival in Mexican women. Int J Gynaecol Obstet 75 1 (2001) 33-42
77. Eluf-Neto J., Booth M., Munoz N., Bosch F.X., Meijer C.J., and Walboomers J.M. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 69 1 (1994) 114-119
78. Lorenzato F., Ho L., Terry G., Singer A., Santos L.C., De Lucena Batista R., et al. The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil). Int J Gynecol Cancer 10 2 (2000) 143-150
79. Noronha V., Mello W., Villa L., Brito A., Macedo R., Bisi F., et al. Papilomavírus humano associado a lesões de cérvice uterina. Rev Soc Bras Med Trop 32 3 (1999) 235-240
80. Rabelo-Santos S.H., Zeferino L., Villa L.L., Sobrinho J.P., Amaral R.G., and Magalhaes A.V. Human papillomavirus prevalence among women with cervical intraepithelial neoplasia III and invasive cervical cancer from Goiania, Brazil. Mem Inst Oswaldo Cruz 98 2 (2003) 181-184
81. Torroella-Kouri M., Morsberger S., Carrillo A., Mohar A., Meneses A., Ibarra M., et al. HPV prevalence among Mexican women with neoplastic and normal cervixes. Gynecol Oncol 70 1 (1998) 115-120
82. Santos C., Munoz N., Klug S., Almonte M., Guerrero I., Alvarez M., et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 85 7 (2001) 966-971
83. Primera Encuesta Nacional de Factores de Riesgo. First ed. (2006), Ministerio de Salud y Ambiente de la Nación, Buenos Aires
84. Subprograma de Detección Precóz de Cáncer de Cuello Uterino. Aprobado por Resolución Ministerial N 480/98 (1998), Programa Nacional de Control de Cáncer. Dirección Nacional de Medicina Sanitaria. Subsecretaría de Programas de Prevención y Promoción. Subsecretaría de Atención Sanitaria. Ministerio de Salud, Argentina
85. Lo que usted debe saber sobre el cáncer de cuello uterino. Argentina: Instituto Nacional de Enfermedades Respiratorias "Dr. Emilio Coni". Administración Nacional de Laboratorios e Institutos de Salud "Carlos G. Malbrán". Subsecretaría de Investigación y Tecnología. Ministerio de Salud; 2000: PRO.CA.28/2000. Available from: http://www.msal.gov.ar/htm/site/pdf/LO%20QUE%20USTED%20DEBE%20SABER%20SOBRE%20CANCER.pdf [Cited: November 4, 2008].
86. Prevenção do câncer do colo do útero. Normas e Recomendações do INCA. Rev Bras Cancerol 49 4 (2003) 205
87. Pesquisa Nacional Por Amostra de Domicílios. Instituto Brasileiro de Geografia e Estatística-IBGE; 2003. Available from: ftp://ftp.ibge.gov.br/Trabalho_e_Rendimento/Pesquisa_Nacional_por_Amostra_de_Domicilios_anual/2003/PNAD_Saude/Brasil [Cited: November 1, 2008].
88. Guía Clínica. Cáncer Cervicouterino. Garantías Explícitas en Salud. First ed. Santiago, Chile: Ministerio de Salud de Chile; 2005. Available from: www.minsal.cl/ici/guiasclinicas/CancerCervicouterino.pdf [Cited: November 4, 2008].
89. Diagnóstico y tratamiento. Cáncer cervicouterino. Protocolo AUGE (2004), Comisión Nacional de Cáncer Cervicouterino. Ministerio de Salud de Chile, Chile
90. Programa de Acción: Cáncer Cervico Uterino. First ed. (2002), Secretaría de Salud. Subsecretaría de Prevención y Protección de la Salud, Mexico DF, Mexico
91. Encuesta Demográfica y de Salud Familiar-ENDES Continua. Instituto Nacional de Estadísticas e Informática, Perú; 2004. Available from: http://www1.inei.gob.pe/web/Endes/ [Cited: October 29, 2008].
92. Manual de normas y procedimientos para la prevención del cáncer de cuello uterino. Perú: Instituto Especializado de Enfermedades Neoplásicas "Dr. Eduardo Cáceres Graziani". Dirección General de Salud de las Personas. Ministerio de Salud; 2004.
93. Matos E., Loria D., Amestoy G.M., Herrera L., Prince M.A., Moreno J., et al. Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis 30 8 (2003) 593-599
94. Estadísticas vitales. Información básica-2005 (2006), Dirección de Estadísticas e Información de Salud. Secretaría de Políticas, Regulación y Relaciones Sanitarias. Ministerio de Salud y Ambiente de la Nación, Buenos Aires
95. Girianelli V.R., Thuler L.C., Szklo M., Donato A., Zardo L.M., Lozana J.A., et al. Comparison of human papillomavirus DNA tests, liquid-based cytology and conventional cytology for the early detection of cervix uteri cancer. Eur J Cancer Prev 15 6 (2006) 504-510
96. Longatto-Filho A., Erzen M., Branca M., Roteli-Martins C., Naud P., Derchain S.F., et al. Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study. Int J Gynecol Cancer 16 3 (2006) 955-962
97. Estimativa 2006: Incidência de câncer no Brasil (2005), Instituto Nacional de Câncer, Rio de Janeiro
98. Informaçoes de Saúde. Mortalidade-Brasil. Ministério da Saúde. Available from: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sim/cnv/obtuf [Cited: March 16, 2008].
99. Ferreccio C., Prado R.B., Luzoro A.V., Ampuero S.L., Snijders P.J., Meijer C.J., et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 13 12 (2004) 2271-2276
100. Donoso S.E., Cuello F.M., and Villarroel Del P.L. Reducción de la mortalidad por cáncer cérvico uterino en Chile, 1990-2003. Rev Chil Obstet Ginecol 71 5 (2006) 307-312
101. Giuliano A.R., Denman C., Guernsey de Zapien J., Navarro Henze J.L., Ortega L., Djambazov B., et al. Design and results of the USA-Mexico border human papillomavirus (HPV), cervical dysplasia, and Chlamydia trachomatis study. Rev Panam Salud Publica 9 3 (2001) 172-181
102. Salmeron J., Lazcano-Ponce E., Lorincz A., Hernandez M., Hernandez P., Leyva A., et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 14 6 (2003) 505-512
103. Egresos hospitalarios, principales causas, 2005. Sistema Nacional de Información en Salud. Secretaría de Salud, México; 2006. Available from: http://sinais.salud.gob.mx/egresoshospitalarios/#top [Cited: May 20, 2008].